Answer Questions About Myinfla for CV Risk Reduction
December 2021
You'll hear about Myinfla (extended-release colchicine) to reduce the risk of CV events in patients with coronary artery disease (CAD).
We're used to seeing immediate-release colchicine 0.6 mg for gout...or off-label for pericarditis.
But there's growing interest in using colchicine's anti-inflammatory effects for other cardiac indications...since inflammation is thought to be a CV risk factor.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive